Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.51) by 5.88 percent. This is a 8 percent decrease over losses of $(0.50) per share from the same period last year.